The proatherogenic properties of lipoprotein(a) may be enhanced through the formation of circulating immune complexes containing Chlamydia pneumaniae-specific IgG antibodies

European Heart Journal

Volumn 21, Issue 8, 2000, Pages 639-646

  Glader, C A ^a   Boman, J ^a   Saikku, P ^a   Stenlund, H ^b   Weinehall, L ^b   Hallmanns, G ^b   Dahlen G H ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Acute myocardial infarction; Case control study; Chlamydia pneumoniae; Circulating immune complex; Lipoprotein(a)

Indexed keywords

IMMUNOGLOBULIN G; LIPOPROTEIN A;

ACUTE HEART INFARCTION; ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; ATHEROGENESIS; CASE CONTROL STUDY; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ANTIBODIES, BACTERIAL; ANTIGEN-ANTIBODY COMPLEX; ARTERIOSCLEROSIS; CASE-CONTROL STUDIES; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; LIPOPROTEIN(A); LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION;

EID: 0034078713     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1999.1755     Document Type: Article

References (36)

1. Dahlén GH, Ericson C, Furberg C, Lundkvist L, Svärdsudd K. Studies on an extra pre-beta lipoprotein fraction. Acta Med Scan (Suppl). 531:1972;1-29.
2. Dahlén GH. Lipoprotein(a) as a risk factor for atherosclerotic diseases. Arctic Med Res. 47:1988;458-461.
3. Rhoads GG, Dahlén GH, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 256:1986;2540-2544.
4. Dahlén GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AMJ. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 74:1986;758-765.
5. Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G, Quinici GB. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis. 38:1981;51-61.
6. Dahlén GH, Weinehall L, Stenlund H. Lipoprotein(a) and cholesterol levels act synergistically and apolipoprotein-A1 is protective for the incidence of primary acute myocardial infarction in middle-aged males. J Intern Med. 1998:1998;425-430.
7. Weinehall, L, Partnership for health; On the role of primary health care in a community intervention programme. Umeå, Sweden, Umeå University.
8. Tunstall-Pedoe H. The World Health Organization MONICA Project (Monitoring of Trends and Determinants in Cardiovascular Disease): A major international collaboration. J Clin Epidemiol. 1988;105-114.
9. Linnanmäki E, Leinonen M, Mattila K, Nieminen MS, Valtonen V, Saikku P. Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation. 87:1993;1130-1134.
10. Wang SP, Grayston JT. Microimmunofluorescense serological studies with the TWAR organism. Oriel JD, Ridgeway G, Schachter J, Taylor-Robinson D, Ward M. Chlamydial infections. 1986;329-332 Cambridge University Press, Cambridge.
11. Hallqvist J, Ahlbom A, Diderichsen F, Reuterwall C. How to evaluate interaction between causes: a review of practices in cardiovascular epidemiology. J Intern Med. 239:1996;377-382.
12. Rothman KJ. Interactions between causes. Modern epidemiology. 1986;Little, Brown, Boston. p. 315-20.
13. Saikku P, Leinonen M, Mattila K. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 2:1988;983-986.
14. Dahlén GH, Boman J, Birgander LS, Lindblom B. Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease. Atherosclerosis. 114:1995;165-174.
15. Grayston JT, Campbell LA, Kuo CC. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis. 161:1990;618-625.
16. Campbell LA, O'Brien ER, Cappuccio AL. Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect Dis. 172:1995;585-588.
17. Puolakkainen M, Kuo CC, Shor A, Wang SP, Grayston JT, Campbell LA. Serological response to Chlamydia pneumoniae in adults with coronary arterial fatty streaks and fibrolipid plaques. J Clin Microbiol. 31:1993;2212-2214.
18. Saikku P, Leinonen M, Tenkanen L. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med. 116:1992;273-278.
19. Ridker PM, Kundsin RB, Stampfer MJ, Poulin S, Hennekens CH. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation. 99:1999;1161-1164.
20. Moss TR, Darougar S, Woodland RM, Nathan M, Dines RJ, Cathrine V. Antibodies to Chlamydia species in patients attending a genitourinary clinic and the impact of antibodies to C. pneumoniae and C. psittaci on the sensitivity and the specificity of C. trachomatis serology tests. Sex Transm Dis. 20:1993;61-65.
21. Ozanne G, Lefebvre J. Specificity of the microimmunofluorescence assay for the serodiagnosis of Chlamydia pneumoniae infections. Can J Microbiol. 38:1992;1185-1189.
22. Kutlin A, Tsumura N, Emre U, Roblin PM, Hammerschlag MR. Evaluation of Chlamydia immunoglobulin M (IgM), IgG, and IgA rELISAs Medac for diagnosis of Chlamydia pneumoniae infection. Clin Diagn Lab Immunol. 4:1997;213-216.
23. Füst G, Szondy é, Székely J, Nánai I, Gerö S. Studies on the occurrence of circulating immune complexes in vascular diseases. Atherosclerosis. 29:1978;181-190.
24. Maisch B, Mayer E, Schubert U, Berg PA, Kochsiek K. Immune reactions in infective endocarditis. II. Relevance of circulating immune complexes, serum inhibition factors, lymphocytotoxic reactions, and antibody-dependent cellular cytotoxicity against cardiac target cells. Am Heart J. 106:1983;338-344.
25. Gallagher PJ, Jones DB, Casey CR, Sharratt GP. Circulating immune complexes in cardiac disease. Atherosclerosis. 44:1982;241-244.
26. Cristea A, Rus H, Niculescu F, Bedeleanu D, Vlaicu R. Characterization of circulating immune complexes in heart disease. Immunol Lett. 13:1986;45-49.
27. Farrell C, Bloth B, Nielsen H, Daugharty H, Lundman T, Svehag SE. A survey for circulating immune complexes in patients with acute myocardial infarction. Use of a C1q-binding assay with soluble protein A as indicator. Scand J Immunol. 6:1977;1233-1240.
28. Smith GW, McArthur CJ, Simpson IJ. Circulating immune complexes in myocardial infarction. J Clin Lab Immunol. 12:1983;197-199.
29. Tertov VV, Orekhov AN, Sayadyan KS. Correlation between cholesterol content in circulating immune complexes and atherogenic properties of CHD patients' serum manifested in cell culture. Atherosclerosis. 81:1990;183-189.
30. McLean JW, Tomlinson JE, Kuang WJ. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 330:1987;132-137.
31. Dahlén GH. Indications of an autoimmune component in Lp(a) associated disorders. Eur J Immunogenet. 21:1994;301-312.
32. Young, CL, Baker, WC, Tomaselli, CM, Dayhoff, MO, Serine Proteases, Dayhoff, MO, Atlas of protein sequence and structure. Silver Spring, MD, National Biomedical Research Foundation, 1978, 5, 73.
33. Dahlén GH, Stenlund H. Lp(a) lipoprotein is a major risk factor for cardiovascular disease: pathogenic mechanisms and clinical significance. Clin Genet. 52:1997;272-280.
34. Kaukoranta Tolvanen SS, Teppo AM, Laitinen K, Saikku P, Linnavuori K, Leinonen M. Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microb Pathog. 1996;215-221.
35. Kuo CC, Gown AM, Benditt EP, Grayston JT. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb. 13:1993;1501-1504.
36. Gianturco SH, Bradley WA, Dahlén GH. Interaction of lipoprotein(a) with murine peritoneal macrophages and cultured human fibroblasts (Abstr). Arteriosclerosis. 3:1983;500a.